Prices are updated after-hours


Sort by: after hours percent change | delayed percent change | gain open | gain high | gain close | publishing date

symbols : NVAX    save search

Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
Published: 2022-08-15 (Crawled : 13:20) - biospace.com/
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 3.86% H: 1.6% C: -0.42%

covid-19 fda for application authorization
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
Published: 2022-08-12 (Crawled : 14:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 1.39% H: 0.0% C: 0.0%

covid-19 for vaccine approved
Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights
Published: 2022-08-08 (Crawled : 22:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: -3.76% H: 0.0% C: 0.0%

results
Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
Published: 2022-08-04 (Crawled : 13:20) - biospace.com/
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 0.31% H: 3.16% C: 1.03%

covid-19 global for children vaccine six trial
Novavax to Host Conference Call to Discuss Second Quarter 2022 Financial Results and Operational Highlights on August 8, 2022
Published: 2022-08-01 (Crawled : 21:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: -1.36% H: 4.67% C: 0.28%

conference results
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17
Published: 2022-07-26 (Crawled : 12:20) - biospace.com/
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 0.53% H: 6.0% C: 2.08%

covid-19 australia for vaccine granted
Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan
Published: 2022-07-26 (Crawled : 12:20) - prnewswire.com
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 0.53% H: 6.0% C: 2.08%

covid-19 for japan vaccine approval
U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older
Published: 2022-07-19 (Crawled : 21:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: -0.16% H: 11.38% C: 2.87%

covid-19 for
Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes
Published: 2022-07-19 (Crawled : 13:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: -4.39% H: 13.25% C: 10.02%

covid-19 vaccine agreement bioscience
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
Published: 2022-07-13 (Crawled : 22:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: -4.42% H: 2.36% C: -22.79%

covid-19 fda for grants authorization emergency use authorization
U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine
Published: 2022-07-11 (Crawled : 12:20) - prnewswire.com
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 2.85% H: 1.68% C: -9.36%

covid-19 vaccine
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
Published: 2022-07-05 (Crawled : 14:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 8.77% H: 13.79% C: 13.27%

covid-19 for authorized vaccine
NOVAVAX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Novavax, Inc. - NVAX
Published: 2022-07-02 (Crawled : 04:20) - prnewswire.com
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

initiated
Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants
Published: 2022-06-28 (Crawled : 23:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: -2.27% H: 6.45% C: 3.91%

covid-19 fda antibody meeting prototype
Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17
Published: 2022-06-23 (Crawled : 19:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: -0.06% H: 0.5% C: -0.21%

covid-19 for chmp vaccine authorization
Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: -4.23% H: 3.34% C: -6.74%

covid-19 australia vaccine
FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older
Published: 2022-06-07 (Crawled : 22:00) - prnewswire.com
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 10.03% H: 1.22% C: -4.21%

covid-19 fda for vaccine authorization order emergency use authorization
Novavax Reports First Quarter 2022 Financial Results and Operational Highlights
Published: 2022-05-09 (Crawled : 22:00) - biospace.com/
TAK | $14.17 -0.49% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: -0.69% H: 0.28% C: -1.1%
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 0.09% H: 5.27% C: -7.13%

results
Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022
Published: 2022-05-02 (Crawled : 21:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: -0.38% H: 19.8% C: 19.71%

conference results
FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine
Published: 2022-04-29 (Crawled : 19:00) - biospace.com/
NVAX | $42.87 1.35% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 3.79% H: 14.21% C: -1.92%

covid-19 fda vaccine review
Top 10 Gainers
APRN 4 | $5.38 16.2% 18.96% | twitter stocktwits trandingview |
Retail Trade

AIM 4 | $0.742 -5.5% 6.47% | twitter stocktwits trandingview |
Health Technology

AAMC | $20.0 1.27% 5.75% | twitter stocktwits trandingview |
Finance

AINC 4 | $18.75 6.05% 5.71% | twitter stocktwits trandingview |
Finance

AUD 4 | $0.7112 -2.52% 5.46% | twitter stocktwits trandingview |
Information

A | $132.77 -0.84% 5.45% | twitter stocktwits trandingview |
Health Technology

IDR | $5.9 -4.06% 5.42% | twitter stocktwits trandingview |
n/a

INTT 4 | $9.77 -4.78% 5.22% | twitter stocktwits trandingview |
Electronic Technology

EHAB P | $14.96 -5.91% 5.15% | twitter stocktwits trandingview |
n/a

CINT | $13.68 -8.62% 5.12% | twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.